ReviewInsights into imaging2026
Spectral CT imaging in colorectal cancer: current applications, limitations, and future perspectives.
Review in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- What you don't see matters: dual-energy CT in emergency radiology.Japanese journal of radiology · 2026Review
- Liver metastases beyond classical imaging findings.Abdominal radiology (New York) · 2026Review
- Development of a nomogram for predicting extramural venous invasion in colon cancer using spectral CT multiparameter imaging.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Multimodal prediction of metachronous liver metastasis in stage I-III colorectal cancer patients: multicenter cohort study employing machine learning.Abdominal radiology (New York) · 2026Article
- Multifocal Peritoneal Mucinous Carcinoma Presenting as Small Bowel Obstruction: A Case Report.Cureus · 2026Article
- Review
- Comparative accuracy of spectral computed tomography and conventional computed tomography in colorectal cancer staging.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the third most common malignancy worldwide, and early detection is vital to prevent metastasis and postoperative recurrence. This review summarizes current applications of spectral computed tomography (CT) in CRC, including its principles, spectral parameters used for evaluating primary and metastatic lesions, and key findings from recent literature. A systematic search of PubMed, Web of Science, and Google Scholar identified English-language studies published between April 2018 and April 2025 using the keywords: "spectral CT," "spectral imaging," "dual-layer spectral CT," "dual-energy spectral CT," "colorectal cancer," and "colon cancer." Spectral CT has shown promise in improving CRC detection and T staging accuracy, increasing sensitivity for lesion characterization, and aiding prognostic assessment after chemotherapy using baseline spectral parameters. Early evidence suggests it may also help predict lymph node metastasis and identify patients at risk of early postoperative metastases or surgical complications. Spectral parameters have been correlated with KRAS mutation, Ki-67 index, microsatellite instability, lymphovascular, perineural, and extramural vascular invasion, as well as microvessel density. However, most studies remain small and observational, highlighting the need for validation in larger, multicenter cohorts. Standardization and the time-intensive nature of image segmentation currently limit widespread adoption. Nevertheless, spectral CT is expected to play an increasing role in CRC evaluation by providing quantitative, predictive imaging biomarkers. Integration with artificial intelligence, particularly deep learning and automated segmentation, will likely expand both research and clinical applications. CRITICAL RELEVANCE STATEMENT: This article explores the current applications of spectral CT in colorectal cancer by outlining the fundamentals of spectral CT, the spectral parameters used to assess, stage, and predict the prognosis of primary and metastatic disease, as well as the main findings from the current literature. KEY POINTS: Spectral CT may be helpful in the detection of colorectal primary tumors, lymph node metastases, and liver metastases, as well as in predicting treatment response. Spectral CT offers a non-invasive method to assess genetic mutations and prognostic factors associated with colorectal primaries. The lack of standardization in technology and measurement methods limits its applicability in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.